All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

pyridostigmine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
acetylcholinesterase inhibitors	2330	155-97-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pyridostigmine pyridostigmine bromide pyridostigmine iodide	A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. Molecular weight: 181.21 Formula: C9H13N2O2 CLOGP: -4.26 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 33.42 ALOGS: -2.32 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.18	g	O
10	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	52 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	76.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	7.60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK	32
kinase-selectivity-class	AXL,BRAF,CDK9,DDR1,GRK2,MAP2K6,MAPK7,MARK4,SIK2,STK33,TEK,TTK	12
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
April 6, 1955	FDA	VALEANT PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myasthenia gravis	896.97	15.63	199	10664	6626	90610958
Myasthenia gravis crisis	547.07	15.63	97	10766	967	90616617
Eyelid ptosis	116.60	15.63	43	10820	8963	90608621
Diplopia	115.09	15.63	60	10803	28654	90588930
Off label use	114.56	15.63	339	10524	1101913	89515671
Thymoma	95.30	15.63	18	10845	260	90617324
Dysphagia	54.13	15.63	67	10796	112211	90505373
Postural orthostatic tachycardia syndrome	45.41	15.63	15	10848	2257	90615327
Myasthenic syndrome	43.66	15.63	10	10853	382	90617202
COVID-19	43.62	15.63	75	10788	168768	90448816
Speech disorder	43.17	15.63	39	10824	45546	90572038
Bradycardia	41.96	15.63	51	10812	83796	90533788
Adiposis dolorosa	40.33	15.63	9	10854	305	90617279
Meningitis aseptic	38.60	15.63	18	10845	6755	90610829
Muscular weakness	37.53	15.63	79	10784	206587	90410997
Drug ineffective	36.32	15.63	286	10577	1384012	89233572
Nocardiosis	35.97	15.63	13	10850	2557	90615027
Cerebral toxoplasmosis	35.15	15.63	11	10852	1394	90616190
Oromandibular dystonia	34.50	15.63	9	10854	594	90616990
Diaphragmatic paralysis	33.22	15.63	9	10854	687	90616897
Blood pressure increased	33.06	15.63	73	10790	197144	90420440
Glucose tolerance impaired	32.88	15.63	17	10846	7968	90609616
Drug ineffective for unapproved indication	32.47	15.63	40	10823	66604	90550980
Therapy non-responder	30.52	15.63	57	10806	136647	90480937
Symptom recurrence	30.52	15.63	13	10850	3946	90613638
Antiacetylcholine receptor antibody positive	28.76	15.63	6	10857	147	90617437
Cholinergic syndrome	28.59	15.63	8	10855	688	90616896
Arthropathy	28.11	15.63	5	10858	366237	90251347
Glossodynia	27.97	15.63	3	10860	321776	90295808
Brain abscess	27.68	15.63	11	10852	2801	90614783
Bulbar palsy	27.65	15.63	5	10858	56	90617528
Systemic lupus erythematosus	27.64	15.63	5	10858	361891	90255693
Ocular myasthenia	27.53	15.63	6	10857	182	90617402
Borderline leprosy	26.83	15.63	4	10859	11	90617573
Product residue present	26.32	15.63	12	10851	4279	90613305
Respiratory distress	25.08	15.63	27	10836	38919	90578665
Rebound effect	24.99	15.63	15	10848	9369	90608215
Asthenia	24.94	15.63	128	10735	533623	90083961
Respiratory failure	24.73	15.63	48	10815	118370	90499214
Product substitution issue	24.50	15.63	19	10844	17989	90599595
Arteriospasm coronary	24.45	15.63	12	10851	5038	90612546
Thymectomy	24.09	15.63	3	10860	0	90617584
Acute on chronic liver failure	23.99	15.63	6	10857	334	90617250
Dysarthria	23.84	15.63	31	10832	54451	90563133
Wound	23.54	15.63	4	10859	302976	90314608
Menopause	22.64	15.63	10	10853	3311	90614273
Wrong patient received product	22.20	15.63	10	10853	3467	90614117
Sinoatrial block	21.56	15.63	7	10856	998	90616586
Suspected COVID-19	21.30	15.63	9	10854	2677	90614907
Hepatitis B surface antibody positive	20.88	15.63	5	10858	232	90617352
Supine hypertension	20.79	15.63	4	10859	64	90617520
Solar lentigo	20.46	15.63	7	10856	1173	90616411
Sensory disturbance	20.40	15.63	16	10847	15397	90602187
Salivary hypersecretion	20.32	15.63	13	10850	9079	90608505
Apnoea	19.91	15.63	13	10850	9401	90608183
Myocardial necrosis marker increased	19.64	15.63	8	10855	2170	90615414
Oral fungal infection	19.44	15.63	9	10854	3323	90614261
Hepatitis B core antibody positive	18.93	15.63	5	10858	346	90617238
Varicella	18.89	15.63	8	10855	2394	90615190
Alopecia	18.78	15.63	19	10844	495052	90122532
Headache	18.63	15.63	171	10692	862575	89755009
Torticollis	18.40	15.63	8	10855	2550	90615034
Lower respiratory tract infection	18.01	15.63	4	10859	250655	90366929
Gastric infection	17.92	15.63	9	10854	3971	90613613
Listeriosis	17.79	15.63	7	10856	1736	90615848
Psoriatic arthropathy	17.76	15.63	3	10860	228332	90389252
Ophthalmic herpes zoster	17.74	15.63	8	10855	2780	90614804
Osmophobia	17.61	15.63	4	10859	147	90617437
Transfusion-related circulatory overload	17.43	15.63	4	10859	154	90617430
Chronic inflammatory demyelinating polyradiculoneuropathy	17.33	15.63	6	10857	1041	90616543
Joint swelling	17.24	15.63	21	10842	503279	90114305
Lack of infusion site rotation	17.21	15.63	4	10859	163	90617421
Condition aggravated	17.12	15.63	126	10737	595419	90022165
SARS-CoV-2 test negative	16.73	15.63	5	10858	543	90617041
Enteritis	16.51	15.63	12	10851	10309	90607275
Cartilage injury	16.43	15.63	7	10856	2124	90615460
Increased bronchial secretion	16.36	15.63	7	10856	2146	90615438
Impaired healing	16.31	15.63	4	10859	234195	90383389
No adverse event	15.98	15.63	29	10834	67953	90549631
Thermal burn	15.94	15.63	10	10853	6752	90610832

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myasthenia gravis crisis	335.12	16.48	65	6929	781	42613560
Myasthenia gravis	333.64	16.48	118	6876	16019	42598322
Eyelid ptosis	189.73	16.48	62	6932	6599	42607742
Diplopia	125.75	16.48	63	6931	20253	42594088
Off label use	60.87	16.48	235	6759	638100	41976241
Myasthenic syndrome	55.84	16.48	15	6979	806	42613535
Muscular weakness	48.53	16.48	64	6930	83434	42530907
Respiratory failure	48.18	16.48	80	6914	128052	42486289
Intestinal transit time decreased	47.52	16.48	9	6985	94	42614247
Glucose tolerance impaired	41.75	16.48	18	6976	4106	42610235
Histoplasmosis	36.60	16.48	13	6981	1774	42612567
Product residue present	34.11	16.48	14	6980	2827	42611514
Osteoporosis	33.29	16.48	24	6970	14882	42599459
Thymoma	32.13	16.48	7	6987	153	42614188
Ocular myasthenia	32.09	16.48	9	6985	568	42613773
Drug ineffective	31.42	16.48	193	6801	630004	41984337
Morvan syndrome	30.53	16.48	5	6989	20	42614321
Ophthalmoplegia	30.42	16.48	12	6982	2188	42612153
Blood bromide increased	28.06	16.48	5	6989	36	42614305
Wrong patient received product	27.85	16.48	13	6981	3570	42610771
Dysphagia	26.74	16.48	45	6949	72674	42541667
Cholinergic syndrome	26.40	16.48	8	6986	663	42613678
Eye luxation	26.15	16.48	4	6990	9	42614332
Asthenia	25.36	16.48	102	6892	280691	42333650
Meningitis aseptic	22.25	16.48	12	6982	4470	42609871
Salivary hypersecretion	20.81	16.48	16	6978	10927	42603414
Myiasis	20.77	16.48	4	6990	46	42614295
Cerebral toxoplasmosis	20.72	16.48	9	6985	2089	42612252
Myopathy	19.59	16.48	17	6977	13744	42600597
Lip swelling	18.43	16.48	19	6975	19034	42595307
Faecal vomiting	17.92	16.48	6	6988	686	42613655
Respiratory muscle weakness	16.96	16.48	4	6990	126	42614215
Rebound effect	16.74	16.48	12	6982	7367	42606974
Symptom recurrence	16.73	16.48	7	6987	1483	42612858
Rash scarlatiniform	16.50	16.48	4	6990	142	42614199

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myasthenia gravis	944.17	14.23	270	15507	21241	110552281
Myasthenia gravis crisis	773.55	14.23	145	15632	1669	110571853
Eyelid ptosis	255.45	14.23	89	15688	13238	110560284
Diplopia	174.00	14.23	95	15682	41799	110531723
Off label use	160.50	14.23	522	15255	1499663	109073859
Thymoma	113.72	14.23	23	15754	401	110573121
Myasthenic syndrome	93.36	14.23	24	15753	1252	110572270
Glucose tolerance impaired	75.81	14.23	34	15743	9803	110563719
Drug ineffective	68.49	14.23	409	15368	1520131	109053391
Dysphagia	66.43	14.23	95	15682	153505	110420017
Respiratory failure	65.12	14.23	113	15664	215219	110358303
Ocular myasthenia	58.71	14.23	15	15762	763	110572759
Muscular weakness	58.37	14.23	117	15660	248351	110325171
Cerebral toxoplasmosis	56.42	14.23	20	15757	3122	110570400
Cholinergic syndrome	55.13	14.23	16	15761	1316	110572206
Wrong patient received product	51.21	14.23	23	15754	6651	110566871
Intestinal transit time decreased	46.62	14.23	9	15768	122	110573400
Drug ineffective for unapproved indication	46.50	14.23	65	15712	102773	110470749
Meningitis aseptic	45.48	14.23	24	15753	9846	110563676
Rebound effect	41.40	14.23	26	15751	14780	110558742
Bradycardia	39.85	14.23	76	15701	155441	110418081
Ophthalmoplegia	39.76	14.23	16	15761	3534	110569988
Adiposis dolorosa	38.77	14.23	9	15768	305	110573217
Salivary hypersecretion	37.54	14.23	26	15751	17395	110556127
Speech disorder	35.72	14.23	44	15733	61525	110511997
COVID-19	34.04	14.23	94	15683	244966	110328556
Nocardiosis	33.92	14.23	18	15759	7468	110566054
Therapy non-responder	33.29	14.23	71	15706	157236	110416286
Bulbar palsy	32.33	14.23	8	15769	357	110573165
Product residue present	31.58	14.23	14	15763	3927	110569595
Morvan syndrome	31.23	14.23	5	15772	20	110573502
Blood pressure increased	30.96	14.23	94	15683	258279	110315243
Postural orthostatic tachycardia syndrome	30.11	14.23	11	15766	1871	110571651
Asthenia	29.26	14.23	183	15594	688816	109884706
Dysarthria	29.20	14.23	47	15730	84074	110489448
Blood bromide increased	28.76	14.23	5	15772	36	110573486
Histoplasmosis	28.62	14.23	12	15765	2941	110570581
Arteriospasm coronary	28.03	14.23	17	15760	9083	110564439
Respiratory distress	27.43	14.23	41	15736	68833	110504689
Oromandibular dystonia	26.70	14.23	9	15768	1210	110572312
Suspected COVID-19	26.68	14.23	12	15765	3481	110570041
Pulmonary nocardiosis	26.54	14.23	11	15766	2618	110570904
Diaphragmatic paralysis	26.17	14.23	9	15768	1285	110572237
Osteopenia	25.77	14.23	23	15754	22186	110551336
Eye luxation	25.19	14.23	4	15773	15	110573507
Sensory disturbance	24.19	14.23	20	15757	17409	110556113
Antiacetylcholine receptor antibody positive	24.11	14.23	6	15771	274	110573248
Atrioventricular block complete	23.71	14.23	21	15756	20061	110553461
Thymectomy	23.57	14.23	3	15774	0	110573522
Menopause	23.55	14.23	10	15767	2528	110570994
Arthropathy	23.52	14.23	6	15771	287516	110286006
Symptom recurrence	23.12	14.23	12	15765	4760	110568762
Therapy partial responder	22.33	14.23	27	15750	37034	110536488
Congenital myasthenic syndrome	21.49	14.23	3	15774	3	110573519
Acute on chronic liver failure	21.48	14.23	6	15771	430	110573092
No adverse event	21.31	14.23	38	15739	73801	110499721
Pericarditis	21.25	14.23	3	15774	219111	110354411
Myiasis	21.02	14.23	4	15773	50	110573472
Neutropenia	20.74	14.23	14	15763	374606	110198916
Borderline leprosy	20.47	14.23	4	15773	58	110573464
Blister	20.09	14.23	4	15773	227372	110346150
Lower respiratory tract infection	20.03	14.23	5	15772	243101	110330421
Pneumonia aspiration	19.94	14.23	39	15738	81194	110492328
Systemic lupus erythematosus	19.52	14.23	6	15771	254332	110319190
Brain abscess	19.20	14.23	12	15765	6762	110566760
Psoriatic arthropathy	18.38	14.23	3	15774	196758	110376764
Irritability	18.38	14.23	28	15749	47781	110525741
Condition aggravated	18.14	14.23	172	15605	734664	109838858
Acute kidney injury	18.01	14.23	40	15737	635390	109938132
Stomatitis	18.00	14.23	8	15769	270234	110303288
Hepatitis B surface antibody positive	17.97	14.23	5	15772	353	110573169
Cyanopsia	17.97	14.23	4	15773	112	110573410
Sinoatrial block	17.79	14.23	7	15770	1458	110572064
Solar lentigo	17.52	14.23	7	15770	1517	110572005
Respiratory muscle weakness	17.18	14.23	5	15772	415	110573107
Wound	17.16	14.23	6	15771	234431	110339091
Osmophobia	17.14	14.23	4	15773	139	110573383
Coma	17.13	14.23	46	15731	117823	110455699
Drug effective for unapproved indication	17.09	14.23	15	15762	14152	110559370
Platelet count decreased	16.69	14.23	6	15771	230437	110343085
Myocardial necrosis marker increased	16.65	14.23	9	15768	3871	110569651
Lack of infusion site rotation	16.64	14.23	4	15773	158	110573364
Myopathy	16.38	14.23	19	15758	24941	110548581
Listeriosis	16.34	14.23	8	15769	2806	110570716
Wheezing	16.31	14.23	8	15769	255222	110318300
Impaired healing	16.29	14.23	4	15773	196713	110376809
Product substitution issue	15.89	14.23	18	15759	23043	110550479
Dropped head syndrome	15.87	14.23	5	15772	543	110572979
Gastric infection	15.86	14.23	9	15768	4257	110569265
Oral fungal infection	15.50	14.23	9	15768	4443	110569079
Respiratory acidosis	15.41	14.23	14	15763	13812	110559710
Torticollis	15.32	14.23	8	15769	3213	110570309
Thermal burn	15.08	14.23	11	15766	7977	110565545
Chronic inflammatory demyelinating polyradiculoneuropathy	15.06	14.23	7	15770	2188	110571334
Joint swelling	15.05	14.23	25	15752	442820	110130702
Hepatitis B core antibody positive	14.96	14.23	5	15772	654	110572868
Diabetes mellitus	14.66	14.23	39	15738	99342	110474180

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N07AA02	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Anticholinesterases
FDA MoA	N0000000177	Cholinesterase Inhibitors
MeSH PA	D002800	Cholinesterase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018678	Cholinergic Agents
FDA EPC	N0000175723	Cholinesterase Inhibitor
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:50514	vasoconstrictor agent
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:55324	gastrointestinal drug

Related Drugs by ATC class:

N07AA Anticholinesterases 3 drugs

ambenoniumdistigmineneostigmine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Myasthenia gravis	indication	91637004	DOID:437
Neuromuscular Block due to Nondepolarizing Drug	indication
Prevention of Nerve Agent Poisoning	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Kidney disease	contraindication	90708001	DOID:557
Gastrointestinal obstruction	contraindication	126765001
Asthma	contraindication	195967001	DOID:2841

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
105MG	PYRIDOSTIGMINE BROMIDE	AMNEAL	N217604	Oct. 4, 2024	DISCN	TABLET, EXTENDED RELEASE	ORAL	11478425	June 18, 2038	PRETREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN	INHIBITOR	IC50	6.44		CHEMBL	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	5.46		CHEMBL
Acetylcholinesterase	Enzyme		ACES_TORCA		IC50	7.09		CHEMBL
Acetylcholinesterase	Enzyme		ACES_BOVIN		Ki	4.71		CHEMBL

External reference:

ID	Source
4019921	VUID
N0000148006	NUI
D00487	KEGG_DRUG
101-26-8	SECONDARY_CAS_RN
4017783	VANDF
4019921	VANDF
C0034261	UMLSCUI
CHEBI:8665	CHEBI
CHEMBL1115	ChEMBL_ID
DB00545	DRUGBANK_ID
CHEMBL812	ChEMBL_ID
D011729	MESH_DESCRIPTOR_UI
4991	PUBCHEM_CID
8994	IUPHAR_LIGAND_ID
19QM69HH21	UNII
9000	RXNORM
46043	MMSL
5392	MMSL
d00363	MMSL
001707	NDDF
004687	NDDF
34915005	SNOMEDCT_US
373344003	SNOMEDCT_US
59953007	SNOMEDCT_US
4685-03-4	SECONDARY_CAS_RN
278	INN_ID
19QM69HH21	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1404	TABLET, EXTENDED RELEASE	180 mg	ORAL	ANDA	12 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2134	TABLET	30 mg	ORAL	ANDA	11 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-3511	TABLET	60 mg	ORAL	ANDA	11 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-3511	TABLET	60 mg	ORAL	ANDA	11 sections
Mestinon	HUMAN PRESCRIPTION DRUG LABEL	1	0187-3010	TABLET	60 mg	ORAL	NDA	15 sections
Mestinon	HUMAN PRESCRIPTION DRUG LABEL	1	0187-3012	SOLUTION	60 mg	ORAL	NDA	15 sections
Mestinon	HUMAN PRESCRIPTION DRUG LABEL	1	0187-3013	TABLET, EXTENDED RELEASE	180 mg	ORAL	NDA	15 sections
Regonol	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3040	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	19 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6622	TABLET	60 mg	ORAL	ANDA	11 sections
Pryidostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	16571-833	SOLUTION	60 mg	ORAL	ANDA	11 sections
PRYIDOSTIGMINE BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	24689-104	SOLUTION	60 mg	ORAL	ANDA	14 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	42192-626	SOLUTION	60 mg	ORAL	ANDA	14 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	47781-335	TABLET, EXTENDED RELEASE	180 mg	ORAL	ANDA	12 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	47781-335	TABLET, EXTENDED RELEASE	180 mg	ORAL	ANDA	12 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	51407-590	TABLET	60 mg	ORAL	ANDA	11 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	58657-810	TABLET	30 mg	ORAL	ANDA	13 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	58657-810	TABLET	30 mg	ORAL	ANDA	13 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	58657-811	TABLET	60 mg	ORAL	ANDA	13 sections
Pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	60846-559	TABLET, EXTENDED RELEASE	105 mg	ORAL	NDA	29 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	62559-470	TABLET	60 mg	ORAL	ANDA	13 sections
Pyridostigmine Bromide	Human Prescription Drug Label	1	64980-220	TABLET	180 mg	ORAL	ANDA	9 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	65841-819	TABLET	60 mg	ORAL	ANDA	11 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	66689-406	SOLUTION	60 mg	ORAL	ANDA	12 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	68084-494	TABLET	60 mg	ORAL	ANDA	15 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-659	TABLET	60 mg	ORAL	ANDA	11 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	68682-301	TABLET, EXTENDED RELEASE	180 mg	ORAL	NDA authorized generic	12 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	68682-302	TABLET	60 mg	ORAL	NDA authorized generic	12 sections
pyridostigmine bromide	HUMAN PRESCRIPTION DRUG LABEL	1	68682-307	SOLUTION	60 mg	ORAL	NDA authorized generic	15 sections
Pyridostigmine Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1731	SOLUTION	60 mg	ORAL	ANDA	11 sections
Pyridostigmine	Human Prescription Drug Label	1	70954-148	SOLUTION	60 mg	ORAL	ANDA	13 sections